Reduced cell surface expression of CCR5 in CCR5Delta 32 heterozygotes is mediated by gene dosage, rather than by receptor sequestration - PubMed (original) (raw)
. 2002 Jan 18;277(3):2287-301.
doi: 10.1074/jbc.M108321200. Epub 2001 Oct 16.
Affiliations
- PMID: 11604406
- DOI: 10.1074/jbc.M108321200
Free article
Reduced cell surface expression of CCR5 in CCR5Delta 32 heterozygotes is mediated by gene dosage, rather than by receptor sequestration
Sundararajan Venkatesan et al. J Biol Chem. 2002.
Free article
Abstract
Macrophage tropic (M-tropic) human immunodeficiency virus (HIV) infection of primary human T cells and macrophages requires optimal cell surface expression of the chemokine receptor CCR5 in addition to CD4. Natural mutations of CCR5 that impair surface expression bestow in the homozygous state complete resistance to M-tropic HIV infection. ccr5Delta32 is the major prototype of such mutants. ccr5Delta32 heterozygosity is associated with delayed onset of AIDS and reduced risk of initial transmission, and this correlates with reduced levels of CCR5 and reduced infectability of CD4+ cells. In addition to gene dosage, sequestration of wild type (WT) CCR5 by mutant protein has been proposed as a mechanism to explain reduced surface expression of CCR5 in cells from ccr5Delta32 and CCR5-893(-) heterozygotes. However, here we demonstrate that a molar excess of ccr5Delta32 or related deletion mutants does not significantly impair the cell surface density of co-expressed WT receptor either in human epithelial cells or Jurkat T cells. Further, ligand-dependent signaling and M-tropic HIV usage of WT receptor are also unaffected. Nascent WT receptor does associate with ccr5Delta32 and related mutant proteins and with other unrelated CC and CXC chemokine receptors under transient labeling conditions. However, using confocal microscopy, we demonstrate that in the steady state, WT and truncated CCR5 proteins segregate into nonoverlapping subcellular compartments. These findings together with the observed and known variability in the cell surface density of CCR5 on quiescent PBLs lead us to conclude that reduced CCR5 gene dosage rather than receptor sequestration is the major determinant of reduced CCR5 expression in cells from ccr5Delta32 heterozygotes.
Similar articles
- Restriction of HIV type 1 infection in macrophages heterozygous for a deletion in the CC-chemokine receptor 5 gene.
Ometto L, Zanchetta M, Cabrelle A, Esposito G, Mainardi M, Chieco-Bianchi L, De Rossi A. Ometto L, et al. AIDS Res Hum Retroviruses. 1999 Nov 1;15(16):1441-52. doi: 10.1089/088922299309955. AIDS Res Hum Retroviruses. 1999. PMID: 10555107 - Role for CCR5Delta32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4+ cells.
Agrawal L, Lu X, Qingwen J, VanHorn-Ali Z, Nicolescu IV, McDermott DH, Murphy PM, Alkhatib G. Agrawal L, et al. J Virol. 2004 Mar;78(5):2277-87. doi: 10.1128/jvi.78.5.2277-2287.2004. J Virol. 2004. PMID: 14963124 Free PMC article. - Association analysis and allelic distribution of deletion in CC chemokine receptor 5 gene (CCR5Δ32) among breast cancer patients of Pakistan.
Fatima F, Saleem S, Hameed A, Haider G, Ali Zaidi SA, Kanwal M, Zehra S, Azhar A. Fatima F, et al. Mol Biol Rep. 2019 Apr;46(2):2387-2394. doi: 10.1007/s11033-019-04699-6. Epub 2019 Mar 8. Mol Biol Rep. 2019. PMID: 30848448 - CCR5Δ32 mutation and HIV infection: basis for curative HIV therapy.
Allers K, Schneider T. Allers K, et al. Curr Opin Virol. 2015 Oct;14:24-9. doi: 10.1016/j.coviro.2015.06.007. Epub 2015 Jul 1. Curr Opin Virol. 2015. PMID: 26143158 Review. - Beyond HIV infection: Neglected and varied impacts of CCR5 and CCR5Δ32 on viral diseases.
Ellwanger JH, Kulmann-Leal B, Kaminski VL, Rodrigues AG, Bragatte MAS, Chies JAB. Ellwanger JH, et al. Virus Res. 2020 Sep;286:198040. doi: 10.1016/j.virusres.2020.198040. Epub 2020 May 30. Virus Res. 2020. PMID: 32479976 Free PMC article. Review.
Cited by
- CCR5Δ32 and HLA allele diversity in bone marrow donors from southern Brazil.
Kulmann-Leal B, Ellwanger JH, Arend AC, Jobim LFJ, Jobim M, Michita RT, Callegari-Jacques SM, Pôrto LCMS, Chies JAB. Kulmann-Leal B, et al. Genet Mol Biol. 2024 Jul 29;47(3):e20230198. doi: 10.1590/1678-4685-GMB-2023-0198. eCollection 2024. Genet Mol Biol. 2024. PMID: 39074297 Free PMC article. - A Pocket Guide to CCR5-Neurotropic Flavivirus Edition.
Garg A, Lim JK. Garg A, et al. Viruses. 2023 Dec 23;16(1):28. doi: 10.3390/v16010028. Viruses. 2023. PMID: 38257729 Free PMC article. Review. - Prevalence of CCR5 Delta 32 Genetic Variant in the Turkmen Population of Golestan Province, Northeast of Iran.
Norasi E, Rastegar M, Hosseini SD, Aghcheli B, Tahamtan A. Norasi E, et al. Biomed Res Int. 2023 Jun 21;2023:8823863. doi: 10.1155/2023/8823863. eCollection 2023. Biomed Res Int. 2023. PMID: 37388364 Free PMC article. - CCR5Δ32 in Brazil: Impacts of a European Genetic Variant on a Highly Admixed Population.
Kulmann-Leal B, Ellwanger JH, Chies JAB. Kulmann-Leal B, et al. Front Immunol. 2021 Dec 10;12:758358. doi: 10.3389/fimmu.2021.758358. eCollection 2021. Front Immunol. 2021. PMID: 34956188 Free PMC article. Review. - CCR5Delta32 deletion as a protective factor in Czech first-wave COVID-19 subjects.
Hubacek JA, Dusek L, Majek O, Adamek V, Cervinkova T, Dlouha D, Pavel J, Adamkova V. Hubacek JA, et al. Physiol Res. 2021 Mar 17;70(1):111-115. doi: 10.33549/physiolres.934647. Physiol Res. 2021. PMID: 33728925 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous